# A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer

> **NCT00354562** · PHASE1,PHASE2 · TERMINATED · sponsor: **Abbott** · enrollment: 75 (actual)

## Conditions studied

- Lung Cancer
- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** ABT-751
- **DRUG:** Placebo
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00354562
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-02
- **Primary completion:** 2008-02
- **Final completion:** —
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2011-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00354562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00354562, "A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00354562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*